The increased circulating levels of transforming growth factor β1 (TGF-β1), found in depressed patients treated with selective reuptake inhibitors, such as sertraline, encouraged the evaluation of sertraline as a potential neuroprotective and anti-inflammatory agent in AD and PD [90,91]. The gene discussed is TGFB1; the disease is Alzheimer disease.